"Another important caveat to our findings is that the threshold for defining cardiotoxicity was set at >30% demonstrating loss of myocardial viability, which limits the definitive interpretation of the results for those drugs with detected viability close to that threshold."
Taxane - Docetaxel - 71.3 ± 6.8%
Topoisomerase inhibitor - Topotecan - 72.2 ± 6.4%
Where does the statistical significance threshold come from? And given these two drugs are close to the threshold, can they also be considered additional potential CPACS opportunities even though HCM viability remained slightly higher than the threshold?
Cardioprotection thread, page-222
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
0.020(1.38%) |
Mkt cap ! $243.8M | |||
| Open | High | Low | Value | Volume |
| $1.47 | $1.47 | $1.47 | $12.40K | 8.441K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5391 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 100 | 1 |
View Market Depth
| Last trade - 10.06am 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.49 |
Change
0.020 ( 1.71 %) |
||||
| Open | High | Low | Volume | ||
| $1.49 | $1.49 | $1.49 | 1228 | ||
| Last updated 10.26am 27/05/2024 ? | |||||
| RAC (ASX) Chart |